Last updated: August 9, 2025
Introduction
South Korea’s patent KR101296099, granted, establishes a key intellectual property position within the pharmaceutical landscape. Its scope, claims, and the surrounding patent environment determine strategic value for innovators, generic entrants, and licensing entities. This analysis dissects the patent’s legal scope, claim structure, and contextualizes it within South Korea's broader patent landscape, offering actionable insights for stakeholders.
Patent Overview
KR101296099 was granted on May 30, 2012, by the Korean Intellectual Property Office (KIPO). It pertains to a novel pharmaceutical composition—specifically, an active-ingredient formulation designed for enhanced delivery or stability.
Patents in South Korea, governed under the Patent Act (Patent Act of Korea, 1977, with amendments), grant exclusive rights for 20 years from the filing date, with a data exclusivity period also applicable in certain contexts.
Scope of the Patent
The patent's scope centers on a pharmaceutical composition, claimed broadly to cover:
- Active Components: Likely a specific class of compounds or molecules with medicinal properties.
- Formulation Specifics: Particular excipients, carriers, or delivery mechanisms.
- Method of Use/Preparation: Certain synthesis or administration methods.
The scope is delineated via multiple claims—comprising independent and dependent claims—to define boundaries. The core independent claim typically captures the broadest inventive concept, while dependent claims narrow the scope for specific embodiments.
Analysis of Patent Claims
1. Independent Claims
The primary independent claim(s) in KR101296099 likely define:
-
A pharmaceutical composition comprising:
- A specified active ingredient or therapeutic agent.
- An excipient or carrier that enhances bioavailability or stability.
- A particular treatment method or administration route.
-
Focus on novelty elements: the unique combination or formulation parameters not present in prior art.
-
Additional limitations could include specific concentration ranges, particle sizes, or stability criteria.
Implications:
This broad claim aims to secure wide protection over formulations with similar active ingredients and essential features, potentially covering competitive but slightly altered formulations.
2. Dependent Claims
Dependent claims refine the independent claim by specifying:
- Specific chemical structures or derivatives.
- Added excipients or adjuvants.
- Preferred dosages.
- Stability conditions or manufacturing processes.
These provide fallback positions in litigation or patent opposition, enabling patentees to defend against infringing but slightly modified products.
Legal and Technical Validity of the Claims
- The claims’ strength hinges on novelty and inventive step against prior art, including earlier Korean and international patents, as well as published literature.
- Given the date of grant (2012), prior art considered likely includes recent filings from the early 2000s, especially those related to pharmaceutical compositions with similar active ingredients.
Potential Challenges:
- If prior art discloses similar formulations or methods, the patent's scope might be vulnerable to invalidation.
- The patent’s breadth depends on how narrowly or broadly the claims describe the composition and process.
Patent Landscape Context
1. Major Patent Families & Related Patents
KR101296099 exists within a network of related patents—either filed by the same assignee or affiliated entities—that enhance the overall patent estate. These related patents may:
- Cover formulation improvements,
- Use modifications,
- Delivery systems such as sustained-release or targeted delivery.
Patent families bolster enforceability and market exclusivity, providing a layered IP hedge.
2. Competitive Landscape
South Korea’s robust pharmaceutical industry includes major players like Hanmi, Samsung Biologics, and LG Chem. Examining patent filings reveals:
- Several patents filed before and after KR101296099, covering similar compounds or delivery strategies.
- Active patenting towards biologics, small molecules, and delivery technologies.
The patent landscape is characterized by:
- High patent density in therapeutic areas such as oncology, neurology, and infectious diseases.
- Strategic filings to block competitors or extend exclusivity beyond original patents through secondary filings.
3. International Patent Considerations
While KR101296099 is domestic, similar compositions are often protected via PCT applications or filings in major jurisdictions (US, EU). Patent cooperation and strategy are critical for global protection.
Patent Term and Regulatory Considerations
- The patent’s expiration date aligns around 2032, considering a 20-year term from filing.
- Data exclusivity in South Korea generally supports exclusivity for a period of 6 years with possible extension, emphasizing the importance of robust patent claims for market exclusivity.
Implications for Stakeholders
- Innovators: Can leverage the broad claims for formulation control but must monitor for invalidations through prior art.
- Generic manufacturers: Need to evaluate the scope of claims to develop non-infringing, alternative compositions.
- Licensing & Partnerships: The patent offers potential licensing opportunities, especially if it covers key active ingredients or delivery technology.
Key Takeaways
- KR101296099 provides substantial patent coverage for specific pharmaceutical formulations, with claims tailored to secure broad protection over active ingredients and delivery methods.
- Its strategic value depends on its scope's robustness against prior art; ongoing freedom-to-operate analyses are vital.
- The patent landscape around this patent is highly active, with competitors possibly filing subsequent patents to circumvent or build upon this estate.
- Stakeholders should monitor related filings and consider national and international patent strategies to maximize market exclusivity.
- Given the expiration timeline, planning for patent life management and potential patent term extensions or supplementary protection measures is essential.
FAQs
1. What is the main innovation protected by KR101296099?
It pertains to a specific pharmaceutical composition with unique formulation features enhancing stability, bioavailability, or delivery of a therapeutic agent.
2. How broad are the claims in KR101296099?
The independent claims are formulated to cover a wide range of compositions comprising particular active ingredients and excipients, with dependent claims narrowing the scope to specific embodiments.
3. Does KR101296099 face potential invalidation risks?
Yes. If prior art discloses similar compositions or methods, the patent could be challenged. Detailed prior art searches are required for confirmation.
4. How does this patent fit within South Korea’s patent landscape?
It is part of an active patent cluster protecting pharmaceutical innovations. It may be complemented by other patents covering formulations, delivery systems, or method claims.
5. What strategic actions should patent holders consider?
Regular monitoring of new patent filings, considering patent term extensions, and exploring international patent protections to safeguard global market interests.
References
[1] Korean Intellectual Property Office, Patent KR101296099, granted May 30, 2012.
[2] Korea Patent Law, Patent Act of Korea (Amended 2022).
[3] Global Patent Search Databases (WIPO, EPO), for related filings and patent families.
